Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVE.
Saved in:
| Title: | Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVE. |
|---|---|
| Authors: | Kileel EM; Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA; Department of Global Health, Boston University School of Public Health, Boston, MA, USA., Malvestutto CD; Division of Infectious Diseases, Ohio State University Medical Center, Columbus, OH, USA., Zanni MV; Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Davies-Smith E; Center for Biostatistics in AIDS Research, Harvard T H Chan School of Public Health, Boston, MA, USA., Fichtenbaum CJ; Division of Infectious Diseases, Department of Medicine, University of Cincinnati, Cincinnati, OH, USA., Lake JE; Department of Medicine, McGovern Medical School, Houston, TX, USA., Lo J; Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Aberg JA; Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Martinez E; Infectious Diseases Service, Hospital Clinic and University of Barcelona, Barcelona, Spain; CIBER de Enfermedades Infecciosas, Institute de Salud Carlos III, Madrid, Spain., Patel K; Center for Biostatistics in AIDS Research, Harvard T H Chan School of Public Health, Boston, MA, USA; Department of Epidemiology, Harvard T H Chan School of Public Health, Boston, MA, USA., Bloomfield GS; Department of Medicine, Duke Global Health Institute and Duke Clinical Research Institute, Duke University, Durham, NC, USA., Chu SM; Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Awwad A; Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Diggs MR; Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Lu AB; Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Bares SH; Division of Infectious Diseases, University of Nebraska Medical Center, Omaha, NE, USA., Berrner D; Division of HIV, Infectious Diseases & Global Medicine, University of California San Francisco at Zuckerberg San Francisco General Hospital, San Francisco, CA, USA., Smieja M; Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada., Okeke NL; Department of Population Health Sciences and Department of Medicine, Duke University School of Medicine, Durham, NC, USA., Kumar P; Division of Infectious Diseases and Travel Medicine, Georgetown University School of Medicine, Washington, DC, USA., João E; Infectious Diseases Department, Hospital Federal dos Servidores do Estado, Rio de Janeiro, Brazil., Currier JS; Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA., Lu MT; Cardiovascular Imaging Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Fox MP; Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA; Department of Global Health, Boston University School of Public Health, Boston, MA, USA., Brennan AT; Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA; Department of Global Health, Boston University School of Public Health, Boston, MA, USA., Douglas PS; Duke University Research Institute, Duke University School of Medicine, Durham, NC, USA., Grinspoon SK; Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. Electronic address: sgrinspoon@mgh.harvard.edu., Ribaudo HJ; Center for Biostatistics in AIDS Research, Harvard T H Chan School of Public Health, Boston, MA, USA. |
| Source: | The lancet. HIV [Lancet HIV] 2026 May; Vol. 13 (5), pp. e306-e315. Date of Electronic Publication: 2026 Mar 27. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101645355 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3018 (Electronic) Linking ISSN: 23523018 NLM ISO Abbreviation: Lancet HIV Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
